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Abstract 
Background: Combination antiretroviral therapy efficiently suppresses HIV replication in infected patients, trans-
forming HIV/AIDS into a chronic disease. Viral resistance does develop however, especially under suboptimal treat-
ment conditions such as poor adherence. As a consequence, continued exploration of novel targets is paramount 
to identify novel antivirals that do not suffer from cross-resistance with existing drugs. One new promising class of 
targets are HIV protein–cofactor interactions. Transportin-SR2 (TRN-SR2) is a β-karyopherin that was recently identified 
as an HIV-1 cofactor. It has been implicated in nuclear import of the viral pre-integration complex and was confirmed 
as a direct binding partner of HIV-1 integrase (IN). Nevertheless, consensus on its mechanism of action is yet to be 
reached.
Results: Here we describe the development and use of an AlphaScreen-based high-throughput screening cascade 
for small molecule inhibitors of the HIV-1 IN–TRN-SR2 interaction. False positives and nonspecific protein–protein 
interaction inhibitors were eliminated through different counterscreens. We identified and confirmed 2 active com-
pound series from an initial screen of 25,608 small molecules. These compounds significantly reduced nuclear import 
of fluorescently labeled HIV particles.
Conclusions: Alphascreen-based high-throughput screening can allow the identification of compounds represent-
ing a novel class of HIV inhibitors. These results corroborate the role of the IN–TRN-SR2 interaction in nuclear import. 
These compounds represent the first in class small molecule inhibitors of HIV-1 nuclear import.
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Background
Control of human immunodeficiency virus type 1 (HIV-
1) infection still poses considerable challenges. Viral 
resistance selection under suboptimal treatment condi-
tions together with long-term adverse effects of chronic 
combination antiretroviral therapy (cART), highlight the 
need for novel antivirals with (1) a higher barrier towards 
resistance development, (2) pharmacokinetic properties 
allowing once-daily dosing and (3) less adverse effects. 
Novel targets, both viral and cellular, therefore need to be 
evaluated for their potential to be targeted with a small 
molecule in order to develop new classes of antivirals. 
HIV is characterized by its ability to stably integrate into 
the host cell genome and to infect both dividing and non-
dividing cells [1]. As a result, the pre-integration complex 
(PIC) needs to be actively transported across the nuclear 
envelope. Integration into host cell chromatin is a com-
plex process catalyzed by the viral integrase (IN). Once 
integration has been achieved, the fate of virus and host 
cell are irreversibly linked, highlighting this step as the 
point-of-no-return in the viral replication cycle.
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Due to technical issues such as poor in vitro solubility, 
IN was last of the three HIV enzymes to be targeted by 
cART. To date, three IN inhibitors have been approved 
for clinical use (raltegravir, elvitegravir and dolutegravir), 
all belonging to a class of catalytic site inhibitors known 
as integrase strand transfer inhibitors (INSTIs, see [2] 
for a recent review). As a consequence of their common 
mechanism of action these inhibitors suffer a significant 
degree of cross-resistance. Allosteric inhibitors potently 
blocking IN indirectly can circumvent cross-resistance 
in analogy to non-nucleoside reverse transcriptase 
inhibitors (NNRTIs) [3]. Of note, successful integration 
and completion of the viral replication cycle in general, 
are dependent on more than just the catalytic activity of 
IN but also on its multimerization dynamics and inter-
play with cellular cofactors such as LEDGF/p75 [4–8]. 
Screening for inhibitors of either the LEDGF/p75-IN 
interaction or the integrase 3′-processing reaction inde-
pendently led to the discovery of a second class of IN 
inhibitors, LEDGINs (also referred to as non-catalytic 
site integrase inhibitors, NCINIs) [9, 10]. By binding 
the LEDGF/p75 binding site across the IN dimerization 
interface, LEDGINs not only block LEDGF/p75 binding 
but also perturb IN multimerization, which in turn leads 
to inhibited catalytic activity (both 3′processing and 
strand transfer) and aberrant viral maturation [4–7, 11, 
12].
In 2008, another IN cofactor was identified, Trans-
portin-SR2 (TRN-SR2, Tnpo3), encoded by the TNPO3 
gene. TRN-SR2 was picked up as a cellular cofactor of 
HIV-1 in two genome-wide siRNA screens [13, 14] 
and as a binding partner of HIV IN in a yeast two-
hybrid screen [15]. Through q-PCR analysis and the 
use of a cellular nuclear import assay [16], Christ et al. 
[15] showed a clear reduction in HIV nuclear import 
after depletion of TRN-SR2, supporting a role of TRN-
SR2 in this process. Transportin-SR2 belongs to the 
β-karyopherin family. It has been shown to import 
splicing factors to the nucleus, most of which contain 
an RS (arginine–serine) repeat region and/or an RNA 
recognition motif (RRM) domain [17–19]. Its overall 
toroid structure, composed of stacked HEAT repeats, 
provides flexibility to accommodate a variety of cellu-
lar cargoes [19–21]. Charged residues on and around an 
Arg-rich helix in TRN-SR2 are critical for recognition 
of the phosphorylated RS region of cargo and hence 
its nuclear import [19]. Until now, crystal structures of 
TRN-SR2 alone [19], in complex with RanGTP [21] and 
in complex with the cellular cargo ASF/SF2 [19] have 
been described. A crystal structure of TRN-SR2 in com-
plex with IN is not available.
A variety of viral components have been linked to 
nuclear import of the HIV pre-integration complex 
(PIC): capsid (CA), the central polypurine tract (cPPT), 
IN, matrix and viral protein R [22–24]. Also for the host 
cell, a plethora of import factors have been implicated, 
most notably importin-α/β [25, 26], importin-α3 [27] 
and importin-7 [28]. Despite the general agreement on 
the importance of TRN-SR2 for HIV nuclear import, the 
exact mechanism of action remains a matter of debate. 
The TRN-SR2–CA interaction has been reported to 
play a role in nuclear import by some groups [29, 30], 
while others published evidence for a direct interaction 
with HIV IN [15, 31–33]. Moreover, IN was shown to 
be displaced from TRN-SR2 upon addition of RanGTP, 
as is the case with normal cargoes [20]. An IN R263A/
K264A mutant is partially deficient for the interaction 
with TRN-SR2 [33, 34] and the corresponding virus was 
affected at the nuclear import step, supporting the notion 
that the IN–TRN-SR2 interaction is responsible for this 
process [34].
As evidenced by the discovery and development 
of LEDGINs, targeting protein–protein interactions 
between IN and cellular cofactors can yield new classes 
of viral replication inhibitors [35, 36]. Since nuclear 
import represents a bottleneck during HIV replica-
tion [15] we reasoned that inhibitors of this interaction 
might have the potential to become potent antivirals 
and we embarked on a drug discovery campaign target-
ing the interaction between HIV-1 IN and TRN-SR2. 
Small molecules disrupting the interaction and block-
ing nuclear import would additionally be valuable to 
study HIV nuclear import and therefore increase our 
understanding of this crucial step in its replication 
cycle.
At the time this study was initiated, the interface 
between TRN-SR2 and IN had not been defined and 
no crystal structure of TRN-SR2 was available. There-
fore, we opted for a high-throughput screening (HTS) 
approach. Here, we describe the development and use 
of an amplified luminescent proximity homogenous 
assay (AlphaScreen)-based screening cascade to iden-
tify small-molecule inhibitors of the HIV-1 IN–TRN-
SR2 interaction from a library of 25,608 compounds. We 
eliminated false positives and nonspecific protein–pro-
tein interaction inhibitors through the implementation 
of appropriate counterscreens. Five compound classes 
provided modest protection against HIV-1 during mul-
tiple round replication. Finally, four representative com-
pounds were tested in a cellular fluorescent HIV nuclear 
import assay. Two compounds significantly reduced the 
number of nuclear PICs, suggesting these molecules rep-
resent a novel class of inhibitors targeting HIV nuclear 
import. These novel inhibitors validate the IN–TRN-SR2 
interaction as an antiviral target and warrant further 
exploration.
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Methods
Recombinant protein purification
Recombinant proteins were expressed in E. coli strain 
BL21-CodonPlus2 (DE3). N-terminally  His6-tagged and 
untagged IN,  His6-tagged glutathione-S-transferase 
(GST-His6), maltose-binding protein (MBP)-tagged JPO2 
(Cell division cycle-associated 7-like protein, CDCA7L), 
3xflag-tagged LEDGF/p75 and GST-TRN-SR2 were puri-
fied as described previously [20, 37–39].
High‑throughput screening
Compound stocks were dissolved at approximately 5 mM 
in dimethylsulfoxide (DMSO) in 96-well plates. Stocks 
were first diluted to 125  µM in assay buffer (150  mM 
NaCl, 25 mM Tris–HCl pH 7.4, 1 mM  MgCl2, 0.1% (v/v) 
Tween-20 and 0.1% (w/v) bovine serum albumin (BSA)) 
supplemented with 2.5% (v/v) DMSO before 10  µl was 
transferred to a dry 384-well PS 384-OptiPlate (Perkin 
Elmer) on a Freedom EVO200 liquid handling robot 
(Tecan). Untagged TRN-SR2 at 2.5 µM and assay buffer 
containing 5% DMSO were transferred from a separate 
96-well plate to the assay plates and represented the posi-
tive and negative controls, respectively. Next, 5  µl each 
of 5×  working dilutions of GST-TRN-SR2 and  His6-IN 
were added using an XRD-384 automated reagent dis-
penser (FluidX). The plate was left to incubate for 1 h at 
7 °C before 5 µl of a glutathione donor and  Ni2+-chelate 
acceptor AlphaScreen bead mixture (Perkin Elmer) was 
added. This brought the final assay volume to 25 µl and 
established final concentrations of 50  µM for the com-
pounds, 10 nM GST-TRN-SR2, 40 nM  His6-IN, 10 µg/ml 
donor and acceptor beads and 2% DMSO.
Hit validation and counterscreens
Both the hit validation assay and the two counterscreens 
(GST-His6 and LEDGF/p75–JPO2) were performed in 
duplicate. Compounds were first diluted to 125  µM as 
during the main screen but now two doses were trans-
ferred to a dry assay plate. From this point on, the hit 
validation assay was performed identically to the main 
screen.
For the GST-His6 counterscreen, 10 µl of a 2.5× work-
ing dilution of the recombinant GST-His6 protein (10 nM 
final assay concentration) was added to the plate instead 
of the GST-TRN-SR2 and  His6-IN. In this case, 50  µM 
bromophenol blue and buffer containing the appropriate 
amount of DMSO represented the positive and negative 
controls, respectively.
The LEDGF/p75–JPO2 specificity counterscreen was 
performed similarly, but instead of GST-TRN-SR2 and 
 His6-IN, maltose-binding protein (MBP)-tagged JPO2 
and 3xflag-tagged LEDGF/p75 were employed at final 
concentrations of 5 nM. The AlphaScreen bead mixture 
was modified accordingly to anti-flag acceptor beads and 
streptavidin donor beads coated with anti-MBP antibody 
according to the manufacturer’s protocol (Perkin Elmer). 
Untagged LEDGF/p75 at a final concentration of 1  µM 
and buffer containing the appropriate amount of DMSO 
were used as positive and negative controls, respectively.
Multiple round antiviral activity assay
The inhibitory effect of antiviral compounds on the HIV-
induced cytopathic effect (CPE) in MT-4 cell culture was 
determined by the MTT-assay [40]. The assay is based 
on the reduction of the yellow colored 3-(4,5-dimethyl-
thiazol-2-yl)-2,5- diphenyltetrazolium bromide (MTT) 
by mitochondrial dehydrogenase of metabolically active 
cells to a blue formazan derivative, which can be meas-
ured spectrophotometrically. The 50% cell culture infec-
tive dose of the HIV strain was determined by titration 
of the virus stock on MT-4 cells. For the antiviral activity 
assays, MT-4 cells were infected with 100–300× 50% cell 
culture infective doses in the presence of five-fold serial 
dilutions of the compounds. The concentration achieving 
50% protection against the HIV CPE (the 50% effective 
concentration,  EC50), was determined as well as the con-
centration killing 50% of the MT-4 cells (the 50% cyto-
toxic concentration,  CC50).
Single round antiviral activity assay
20,000  HeLaP4 cells were seeded into 96-well plates on 
the day prior to infection. Cells were infected in triplicate 
with 3 dilutions (typically 1 × 105, 3.3 × 104 and 1.1 × 104 
pg p24) of VSV-G pseudotyped single-round HIV-1 sup-
plemented with one of the compounds in a total volume 
of 200 µl per well. The virus was produced as described 
previously [31]. The final compound concentration in the 
assay was 100  µM. p24 measurements were performed 
with the Innotest HIV Antigen mAb kit (Fujirebio). 24 h 
after infection the supernatant was replaced by fresh 
medium. 72 h post infection cells were lysed in 50 µl of 
lysis buffer (50  mM Tris/HCl, pH 7.3, 200  mM NaCl, 
0.2% NP40, 5% glycerol) and analyzed for firefly luciferase 
activity (ONE-Glo™, Promega, Belgium) according to the 
manufacturer’s protocol. Chemiluminescence was meas-
ured with a Glomax luminometer (Promega, Belgium). 
The signals were normalized for protein content as deter-
mined by a BCA protein assay (Thermo Scientific Pierce).
PIC nuclear import assay
The PIC nuclear import assay was performed as previ-
ously described [34]. Briefly, to produce the fluorescent 
HIV particles, 293T cells were transfected with 15  µg 
pVpr-IN-eGFP, 15  µg pNL4-3.Luc.R-.E- (obtained from 
the NIH AIDS Reference and Reagent Program), and 5 µg 
of the pMD.G plasmid encoding the vesicular stomatitis 
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virus glycoprotein (VSV-G) [41]. Supernatant was col-
lected after 48  h, filtered and concentrated by ultracen-
trifugation. p24 was measured with the Innotest HIV 
Antigen mAb kit (Fujirebio). A viral inoculum of 3.106 pg 
p24 was used to infect 30,000 HeLaP4 cells in the pres-
ence of 100  µM of hit compound. PF-3450074 (PF74, 
Sigma-Aldrich) was tested at 2 µM and 10 µM. Five hours 
after infection, cells were fixed and the nuclear lamina 
was visualized with a monoclonal anti-lamin A/C anti-
body (Santa Cruz, sc-7292) followed by a secondary goat 
anti-mouse IgG Alexa-Fluor 633. Three-dimensional 
image stacks were acquired on a Zeiss LSM510 mul-
tiphoton confocal microscope (Cell Imaging Core CIC, 
University of Leuven) equipped with a Plan-Apochromat 
63×/1.4 Oil DIC objective. The Z-step size was 0.3 µm. 
The quantification of PICs was performed using a home-
made MatLab routine (The MathWorks, Inc.). A fluores-
cent spot was assigned as a PIC if at least two adjacent 
pixels were above the threshold and if the signal was 
present in at least two consecutive Z-planes. PICs were 
classified as cytoplasmic or nuclear based on the nuclear 
lamin staining.
Results
Optimization of the IN–TRN‑SR2 AlphaScreen
Development of robust high-throughput assays requires 
optimal buffer conditions in which both proteins and 
the detection method are stable and reproducible. Initial 
conditions for an AlphaScreen assay measuring the direct 
protein–protein interaction between HIV-1 IN and TRN-
SR2 were previously reported by our group [31]. This 
experience allowed us to readily adapt an assay buffer 
to meet the requirements for a high-throughput screen 
(HTS) for inhibitors of the interaction. Two modifica-
tions were made to the previously reported assay buffer: 
First, measurements were done in the presence of 1 mM 
dithiothreitol (DTT) to maintain a sufficiently reducing 
environment and prevent aggregation of glutathione-S-
transferase (GST)-tagged protein on the surface of the 
glutathione donor beads [39]. Second, since protein–pro-
tein interactions can be difficult to disrupt by small mol-
ecules, we aimed to screen at a relatively high compound 
concentration of 50  µM. To aid compound solubility at 
these concentrations, aside from the already present 0.1% 
(v/v) Tween-20 and 0.1% (w/v) bovine serum albumin 
(BSA), we increased the final concentration of dimethyl-
sulfoxide (DMSO). To assess the tolerance of the assay 
for DMSO, we titrated it out in a two-fold dilution series 
between 20 and 0.16% (v/v). The AlphaScreen signal was 
normalized to the 0% DMSO condition and the back-
ground signal (100 and 0%, respectively). Figure 1 shows 
that despite a high tolerance of the assay for DMSO the 
variability increases to unacceptable levels when more 
than 2.5% DMSO is present. Based on these results, we 
opted for a final DMSO concentration in the assay buffer 
of 2%.
HTS assay optimization is a fine balance between iden-
tifying robust assay conditions with minimal variability 
and keeping costs acceptable. In the present case, costs 
were mainly driven by the amount of AlphaScreen beads 
used. However, reducing the bead concentration leads 
to a roughly linear decrease of the signal-to-background 
(S/B) ratio, and hence of the assay quality as well [39]. As 
a compromise, we decided to lower the final bead con-
centrations only two-fold to 10 µg/ml.
Next, optimal protein concentrations were deter-
mined through cross-titration of the binding partners 
(Fig.  2a). Concentrations of 10  nM GST-TRN-SR2 and 
40  nM  His6-IN provided a good S/B ratio (>  25) with 
minimal protein consumption and remained well below 
the AlphaScreen hooking range. Hooking can be seen to 
occur at concentrations of 300 nM  His6-IN. Under these 
conditions, the  Ni2+-chelate acceptor beads are expected 
to be fully saturated and the excess of free IN protein will 
compete with IN on the bead surface for binding to TRN-
SR2, effectively inhibiting the signal.
To monitor per plate quality, each 384-well plate con-
tained a total of 64 control wells arranged in 2 columns of 
8 positive and 8 negative wells on either side. As a posi-
tive control, we evaluated both untagged TRN-SR2 and 
IN to corroborate the ability of our assay to pick up inhib-
itors. However, untagged IN proved unable to inhibit the 
AlphaScreen signal to background levels (Fig.  2b), most 
likely due to the proneness of the enzyme to form mul-
timers at higher concentrations [42, 43] which could 
still bring both beads together. Untagged TRN-SR2 did 
inhibit the signal (Fig. 2b) and was chosen as the positive 
control at a final concentration of 1 µM.
Fig. 1 Tolerance for dimethylsulfoxide (DMSO) in the AlphaScreen 
assay. DMSO was titrated out starting from 20% (v/v) in the IN-TRN-
SR2 interaction assay and the resulting AlphaScreen signal was 
measured. Results are normalized to the 0% DMSO condition
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High‑throughput screening, false positives and negatives
The optimized assay was used to screen a part of the CD3 
(Center for Drug Design and Discovery) library. The set 
of test compounds consisted of 25,608 small molecules 
which were selected based on (1) chemical diversity, (2) 
druglike properties (Lipinski rule of five compliant), (3) 
exclusion of known toxicophores and purchased from 
multiple commercial suppliers. Assay performance was 
evaluated on a plate-by-plate basis and remained robust 
throughout the entire screening campaign (Fig.  3). A 
median Z′-factor of 0.76 was obtained and no plates 
failed during screening. Considering a cut-off of 50% 
inhibition (percentage of inhibition (PIN) of 50%), we 
identified a total of 409 initial hits from the collection.
False positives often dominate initial hit lists obtained 
from HTS campaigns. True false positives were weeded 
out from the cherry-picked hit compounds by a con-
firmation screen in which the 409 hits were retested in 
duplicate in the IN–TRN-SR2 interaction assay. Figure 4a 
shows percentages of inhibition (PIN) of the duplicates 
of each compound normalized to the positive (100%) 
and negative (0%) controls. Linear regression results in a 
slope of 1.000 ± 0.004 and an  R2 of 0.9675, indicating the 
robustness of the platform.
AlphaScreen technology is not insensitive to interfer-
ence [44]. To rid our hit lists of AlphaScreen-specific false 
positives including inner filter effect, 1ΔO2 quenchers, 
and  Ni2+ chelators, we included in our cascade a GST-
His6 counterscreen described previously [39]. Figure  4b 
shows PIN values for the duplicates of each compound 
in this counterscreen normalized to the positive (bromo-
phenol blue, inner filter effect, 100%) and negative (0%) 
controls. Here as well, the slope of 0.9892 ± 0.006 and  R2 
of 0.9640 confirm the platform’s robustness.
Combining both results by plotting the average PIN in 
the GST-His6 counterscreen against that from the con-
firmation screen allowed us to confidently select positive 
hits (Fig. 4c). First, we opted for compounds that met the 
cut-off of 50% inhibition of the IN–TRN-SR2 interac-
tion, eliminating 126 false positives. Second, compounds 
should preferentially be devoid of quenching at the active 
concentrations. Specifically, the percentage of inhibition 
in the GST-His6 counterscreen should be below 20% or 
the activity observed against the IN–TRN-SR2 interac-
tion should be > 50% stronger than the quenching. These 
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Fig. 2 Cross-titration of  His6-IN and GST-TRN-SR2 and evaluation of positive controls. a Both proteins were titrated against one another and the 
AlphaScreen signal measured (from yellow/low to red/high signal). The optimal condition containing 10 nM GST-TRN-SR2 and 40 nM  His6-IN is 
indicated with a blue circle. GST, glutathione S-transferase; IN, integrase. b Untagged TRN-SR2 and IN were titrated out in the IN–TRN-SR2 interac-
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Fig. 3 Assay performance throughout the screening campaign. 
Assay performance per plate was monitored throughout the screen-
ing campaign. A median Z’-factor of 0.76 was determined. No plates 
had to be repeated
Page 6 of 13Demeulemeester et al. Retrovirology  (2018) 15:5 
a
b
c
TRN-SR2-IN
50 100
50
100
n 
= 
2 
(P
IN
, %
)
n = 1 (PIN, %)
MVG059
Histogram 98 hits              GST-His6
50 100
50
100
n 
= 
2 
(P
IN
, %
)
n = 1 (PIN, %)
TRN-SR2-IN vs GST-His6
50 100
50
100
20
G
ST
-H
is
6,
 P
IN
 (%
)
TRN-SR2 PIN (%)
JPO2-LEDGF/p75
-8 -7 -6 -5 -4
0
25
50
75
100
log[compound] (M)
   
   
   
PI
N
 (%
)
0
5
10
15
20
< 
5.0 7.5 12
.5
17
.5
22
.5
27
.5
32
.5
37
.5
42
.5
> 
45
.0
IC50 Bin Center (µM)
   
# 
co
m
po
un
ds
0 20 40 60
0
20
40
60
IC50  IN–TRN-SR2 (µM)
IC
50
  (
µM
)
d
e
f
Fig. 4 AlphaScreen screening strategy (a, b). Normalized percentage inhibition (PIN) of duplicates of each of the 409 primary hits in (a) a confirma-
tory repeat of the IN–TRN-SR2 AlphaScreen or (b) the GST-His6 false positive counterscreen. In both cases, the linear regression fit to the data is 
shown: slopes are not significantly different from 1 and  R2 values are 0.9675 and 0.9640 for (a) and (b), respectively. c Average percentage inhibition 
in the GST-His6 counterscreen plotted against that observed in the IN–TRN-SR2 assay. Hits of interest show > 50% inhibition of the IN–TRN-SR2 
interaction and are devoid of quenching at the active concentration (< 20% inhibition of the GST-His6 signal or 50% stronger inhibition of the 
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squares (quenchers) and black circles (hits of interest). d Titration results and dose–response curve fit obtained for compound MVG059. Duplicates 
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10 and 3 times more active in the IN–TRN-SR2 assay are less promising (light grey squares). Those that were less potent  (IC50 ≥ 20 µM) but did not 
inhibit the LEDGF/p75–JPO2 interaction  (IC50 > 60 µM) were looked at case-by-case. Compounds falling outside of these regions were considered 
non-specific and not investigated further (dark grey triangles)
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requirements delineated an area of the results space con-
taining 98 clean and confirmed hit compounds (Fig. 4c, 
black circles).
Determination of potency and specificity
The 98 confirmed hits were next subjected to  IC50 deter-
mination in the IN–TRN-SR2 AlphaScreen interaction 
assay. Compounds were titrated in duplicate in a three-
fold dilution series starting at 50 µM and dose–response 
curves were fit to the resulting data. Figure  4d shows a 
representative titration result while Fig. 4e provides a his-
togram of the obtained  IC50 data. In total, 14 out of the 
98 hits had an  IC50 value in the single digit micromolar 
range.
Since the IN–TRN-SR2 protein–protein interface is 
believed to be relatively flat and featureless, we decided 
to perform a specificity counterscreen. Compounds were 
assayed for their inhibition of an unrelated protein–pro-
tein interaction (LEDGF/p75–JPO2) [45, 46] and their 
 IC50 values were determined. Compounds were titrated 
as before and the inhibition of the interaction between 
full-length 3xflag-tagged LEDGF/p75 and MBP-tagged 
JPO2 was measured by AlphaScreen. Dose–response 
curves were fit and the resulting  IC50 values compared to 
those obtained for the IN–TRN-SR2 interaction. Com-
pounds that showed high activity  (IC50 < 20 µM) in the 
IN–TRN-SR2 interaction assay and were tenfold less 
active or completely inactive  (IC50 > 60 µM) against the 
LEDGF/p75–JPO2 interaction were prioritized (Fig. 4f ). 
Compounds that were between 10 and 3 times more 
active in the IN–TRN-SR2 assay were kept as back-up 
compounds. Those that were less potent  (IC50 ≥ 20 µM) 
but did not inhibit the LEDGF/p75–JPO2 interaction 
 (IC50  >  60  µM) were looked at case-by-case and evalu-
ated as potential back-up compounds based on their PIN 
at the highest concentration used. All compounds falling 
outside these regions of the results space were considered 
nonspecific protein–protein interaction inhibitors and 
discarded from the hit list. In the end, this resulted in 23 
first priority and 25 fallback compounds.
Analogues
The 23 first priority compounds were clustered into 12 
classes based on their structure and the hit compounds 
of each cluster were repurchased. Unfortunately, the 
IN–TRN-SR2 activity could not be confirmed for 5 hits 
which left us with 7 hit compounds for which commer-
cially available analogues were selected and ordered. 
These analogues were funneled through the same screen-
ing cascade consisting of the IN–TRN-SR2 interaction 
assay and both counterscreens (GST-His6 for quench-
ing and LEDGF/p75–JPO2 for specificity) leading to a 
selection of compounds which were further evaluated for 
inhibition of HIV-1 replication and cellular toxicity in the 
MTT/MT-4 viral replication assay (see Table 1).
Antiviral activity in cell culture
A selection of active compounds was then evaluated for 
inhibition of HIV-1 replication and cellular toxicity in the 
MTT/MT-4 viral replication assay. The percentage pro-
tection against the HIV CPE was measured. Modest (up 
to 46% at 100 µM) protection was observed for a limited 
number of compounds in classes 3, 7 and 9 but no 50% 
effective concentration  (EC50) was reached at concentra-
tions lower than the observed 50% cytotoxic concentra-
tion  (CC50) (Table 1).
Rapid growth (and frequent cell divisions) of the MT-4 
cells during the viral replication assay however, may 
mask viral nuclear import defects, in particular with low 
potency compounds. This could imply that the MTT/
MT-4 assay is not well suited to detect a block in viral 
nuclear import. We hence decided to evaluate four rep-
resentative compounds from the most promising classes 
6, 7, 9 and 10 in a single round antiviral activity assay on 
HeLaP4 cells. Compounds were tested at a final concen-
tration of 100 µM and cells were infected with a threefold 
dilution series of a single-round virus expressing the fire-
fly luciferase reporter gene (Fluc). The percentage inhibi-
tion of HIV replication compared to the DMSO control 
was determined. For compound MVG036 no inhibi-
tion could be detected while MVG010, MVG044 and 
MVG030 showed 34.2, 16.3 and 23.3% inhibition, respec-
tively (Fig. 5).
Effect on HIV nuclear import
We next analyzed the selected compounds, again at 
100 µM concentration, in a low throughput PIC nuclear 
import assay [34] to test whether the decrease in viral 
replication is due to inhibition of PIC nuclear import. 
In this assay fluorescently labeled viral PICs are visual-
ized using confocal microscopy and their subcellular 
localization is evaluated based on a nuclear lamina stain-
ing (Fig.  6a, b). The ratio of nuclear PICs over the total 
number of PICs (percentage nuclear PICs) was then 
calculated as a measure of nuclear import. DMSO and 
Raltegravir (RAL) were used as negative controls in two 
independent experiments as they should not affect HIV 
nuclear import. The capsid-binder PF74 was used as 
a positive control. This compound is known to inhibit 
nuclear import at low concentrations (2 µM) whereas it 
also inhibits reverse transcription at higher concentra-
tions (10 µM) (Fig. 6c) [47, 48]. MVG044 and MVG030 
significantly reduced the number of nuclear PICs com-
pared to both DMSO and RAL (p < 0.05) while MVG036 
only showed significance compared to DMSO (Fig.  6d; 
Table 2).
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Table 1 Antiviral activity and toxicity of selected hits in multiple round MTT assay
Class Compound ID IN–TRN‑SR2 Pin at 50 µM (%)a EC50 (µM)
b CC50 (µM)
c Protection (%)d
3 MVG001 65.3 < 8 < 8 2
MVG002 43.4 > 13 = 13 5
MVG003 47.2 > 80 = 80 13
MVG004 82.6 > 21 = 21 4
MVG005 39.7 > 57 = 57 6
MVG006 50.5 > 63 = 63 6
MVG007 64.8 > 74 = 74 6
MVG008 30.1 > 99 = 99 23
MVG009 32.0 > 51 = 51 4
6 MVG010 37.1 > 100 = 100 6
MVG011 41.7 > 102 = 102 1
MVG012 107.1 > 74 = 74 10
MVG013 51.9 > 95 = 95 3
MVG014 63.8 > 87 = 87 4
MVG015 48.1 > 87 = 87 5
MVG016 46.9 > 244 > 244 20
MVG017 < 10 = 195 = 229 52
MVG018 < 10 > 137 > 137 7
MVG019 < 10 > 250 > 250 6
MVG020 < 10 > 250 > 250 18
MVG021 < 10 > 250 > 250 34
MVG022 44.9 = 67 > 136 53
MVG023 < 10 > 110 > 110 0
MVG024 < 10 > 36 > 45 49
7 MVG025 72.9 > 34 = 34 4
MVG026 45.7 > 35 = 48 4
MVG027 43.2 > 57 = 57 6
MVG028 58.7 > 56 = 80 13
MVG029 48.8 > 57 = 57 3
MVG030 71.6 > 97 = 97 25
MVG031 62.3 > 53 = 53 4
MVG032 46.5 > 48 = 48 5
MVG033 49.5 > 59 = 59 20
MVG034 43.0 > 73 = 73 16
9 MVG035 43.8 > 36 = 36 1
MVG036 105.6 > 55 = 65 46
MVG037 43.1 > 85 = 85 22
MVG038 47.2 > 59 = 59 0
MVG039 40.1 > 17 = 17 1
MVG040 43.6 > 25 = 25 25
MVG041 54.0 > 35 = 35 2
10 MVG042 89.6 > 55 = 55 10
MVG043 102.0 > 67 = 67 4
MVG044 75.9 > 250 > 250 22
MVG045 11.4 > 203 = 203 21
MVG046 10.3 > 207 = 207 32
MVG047 < 10 > 250 > 250 7
MVG048 < 10 > 87 = 87 0
MVG049 < 10 = 165 > 231 55
MVG050 44.1 > 250 > 250 0
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MVG044 from compound family 10 induced the most 
pronounced block to nuclear import: the mean  % nuclear 
PICs was 4.8% for DMSO (95% confidence interval [3.8; 
5.9%]), 4.5% for Ral [3.4; 5.6%] and 2.1% [0.9; 3.2%] and 
2.0% [1.5; 2.7%] for the two MVG044 conditions (DMSO, 
n = 49 cells; MVG044, n = 50 cells; p = 0.00001, Mann–
Whitney U test and Ral, n = 35 cells; MVG044, n = 31 
cells; p = 0.0002, Mann–Whitney U test) (Table 2).
In Table 3 we present an overview of the data for the 
four representative compounds. At first sight, there does 
not seem to be a strong correlation between the differ-
ent read outs. This is not entirely unexpected, mainly due 
to the modest activity of our compounds. In addition, 
these compounds are products of commercially avail-
able libraries and have not been optimized yet for activ-
ity. The experiments on the potency determination in 
MT4 cells as well as the inhibition of viral infectivity in a 
single round viral replication assay in HeLaP4 cells, were 
experiments lasting for 5 and 3 days, respectively. Chemi-
cal (in)stability of the compounds might lead to a more 
pronounced effect when early time points are analyzed 
(PIC assay) in contrast to analysis after incubation over 
several days.
Discussion
Here we present the discovery of small HIV-1 nuclear 
import inhibitors targeting the interaction of HIV-1 IN 
and its cellular co-factor, the karyopherin TRN-SR2. We 
developed an AlphaScreen-based HTS assay to screen for 
inhibitors of the HIV IN–TRN-SR2 interaction (Figs. 1, 2, 
3). We screened a diverse library of 25,608 compounds, 
yielding a total of 409 hits (Fig. 4). A confirmation assay 
on the cherry-picked hits in combination with a GST-
His6 counterscreen to remove AlphaScreen technology-
interfering false positives narrowed down the hit list to 
98 inhibitors (Fig. 4c). Of these 98 hits, 14 were found to 
have an  IC50 value in the single-digit micromolar range as 
determined in the TRN-SR2–HIV IN AlphaScreen assay 
(Fig. 4e). Because we anticipated the IN–TRN-SR2 inter-
face to be relatively flat and featureless, we performed an 
additional specificity counterscreen for an unrelated pro-
tein–protein interaction (LEDGF/p75–JPO2). Selecting 
compounds that did not inhibit the LEDGF/p75–JPO2 
interaction or were 10 times more potent against the 
IN–TRN-SR2 interaction resulted in a list of 23 first pri-
ority compounds (Fig. 4f ). After clustering, hit confirma-
tion with a new “fresh” sample, and analogs selection, the 
Table 1 continued
Class Compound ID IN–TRN‑SR2 Pin at 50 µM (%)a EC50 (µM)
b CC50 (µM)
c Protection (%)d
MVG051 < 10 > 250 > 250 22
MVG052 20.1 > 66 = 66 8
MVG053 < 10 > 167 > 167 39
MVG054 18.0 > 225 = 225 0
MVG055 < 10 > 167 > 167 21
MVG056 71.1 > 250 > 250 24
MVG057 23.3 > 250 > 250 16
MVG058 53.7 = 170 > 250 24
a Compounds were tested in AlphaScreen at 50 µM for their ability to inhibit the IN-TRN-SR2 interaction. Percentage inhibition (PIN), relative to the DMSO control
b,c MT-4 cells were infected with HIV at 100 to 300× the 50% cell culture infective doses in the presence of 100 µM of the antiviral drugs. The compound concentration 
achieving 50% protection against the cytopathic effect of HIV, the 50% effective concentration  (EC50), was determined. The concentration of the compound killing 
50% of the MT-4 cells, the 50% cytotoxic concentration  (CC50), was determined as well
d The percentage of protection against the cytopathic effect of HIV was measured in MT-4 cells as well. Values below 20% were not considered as real activities. Data 
are averages of triplicate measurements
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Fig. 5 Representative hit compounds inhibit single round viral repli-
cation. HeLaP4 cells were infected with 3.3 × 104 pg p24 of a single-
round virus expressing the firefly luciferase reporter gene (Fluc) in the 
presence of 100 µM of one of the compounds. After 72 h, cells were 
lysed and the percentage inhibition of HIV replication compared 
to the DMSO control was measured. Mean and standard deviation 
of two independent experiments, each performed in triplicate, are 
presented
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Fig. 6 Representative hit compounds reduce nuclear import of HIV. Five hours after infection with IN-eGFP labeled virus in the presence of one of 
four representative hit compounds (MVG010, MVG044, MVG030 or MVG036), PF74 and DMSO or RAL as controls, HeLaP4 cells were fixed and ana-
lyzed by laser-scanning confocal microscopy. The ratio of nuclear/total amount of PICs was quantified (percentage nuclear PICs). a, b Representa-
tive slice of a stack of cells infected with eGFP-IN labeled virus in the presence of DMSO (a) or MVG044 (b). The nuclear lamina was immunostained 
with anti-lamin a/c (red). PICs are identified as green dots and nuclear PICs are highlighted by white arrows. c, d Presented are the cumulative 
distributions of the percentage of cells containing the indicated percentage nuclear PICs for the positive control PF74 (c) and four representative hit 
compounds (MVG010, MVG044, MVG030 or MVG036) or DMSO and Ral as controls (d). Two independent experiments, with distinct virus produc-
tions, are presented for each compound
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best compounds selected from 6 series were evaluated 
for their ability to block HIV replication in infected cells. 
For five of the classes we were able to detect modest pro-
tection against the HIV CPE in an MTT/MT-4 antiviral 
activity assay (Table 1). In a next step, compounds from 
the most promising classes 6, 7, 9 and 10 were tested in 
a single-round antiviral activity assay and a HIV nuclear 
import assay on HeLaP4 cells. Although only modest 
inhibition of viral replication could be detected (Fig. 5), 
two of the compounds significantly reduced the num-
ber of nuclear PICs while the other two showed a trend 
towards less nuclear import (Fig. 6; Table 3).
As previously mentioned, no information on the struc-
ture and interface of the TRN-SR2–HIV IN complex was 
available at the start of our screening campaign. In 2012, 
De Houwer et al. identified the interaction hot spots in IN 
for the IN–TRN-SR2 interaction [32]. Amino acids R262/
R263/K264 and K266/R269 in the C-terminal domain of 
IN were found to be the main determinants of the inter-
action. These results were independently confirmed by 
Larue et  al. [33]. More recently, the structures of TRN-
SR2 alone and its complexes with Ran-GTP and ASF/SF2 
were published [19, 21]. Although the structure of TRN-
SR2–IN has not yet been solved, structural information 
together with the mutagenesis data point towards a large, 
charged and relatively flat interaction interface. Target-
ing the TRN-SR2–IN interaction with high affinity may 
therefore require design of completely new chemotypes 
[49].
Conclusions
Our efforts evidenced that an Alphascreen-based HTS 
can allow the identification of compounds represent-
ing a novel class of HIV inhibitors. Their activity in the 
PIC nuclear import assay confirms that nuclear import 
of HIV can be targeted by small molecules. While the 
effects are clear-cut in the PIC assay, the activities of the 
compounds in the MTT/MT-4 and the single round anti-
viral activity assay are only modest (Table 3). Several rea-
sons may be conceived to explain this discrepancy. First, 
Table 2 PIC assay statistics
Summary of two independent PIC assays comparing the four representative hit compounds to the DMSO and Ral control. HeLaP4 cells were fixed and analyzed by 
confocal microscopy 5 h after infection with an eGFP-labeled IN virus. PICs were assigned as cytoplasmic or nuclear based on nuclear lamina staining
a Number of HeLaP4 cells counted in each condition
b p values (Mann–Whitney U test) compared to DMSO or RAL control
c Mean percentage of nuclear PICs in each cell calculated using a homemade MatLab routine (The MathWorks, Inc.)
d 95% confidence interval (CI) for the percentage of nuclear PICs
Compared to DMSO Compared to Raltegravir
na p  valueb  % nuclear  PICsc 95%  CId na p  valueb % nuclear  PICsc 95%  CId
DMSO – – – 49 0.8099 4.8 [3.8; 5.9]
Ral 35 0.8099 4.5 [3.4; 5.6] – – –
MVG010 32 0.1209 3.8 [2.3; 5.4] 29 0.1152 4.2 [2.2; 6.3]
MVG044 31 0.00001 2.1 [1.5; 2.7] 50 0.0002 2.0 [0.9; 3.2]
MVG030 30 0.0411 3.3 [2.3; 4.2] 33 0.0019 2.2 [1.4; 3.0]
MVG036 31 0.0011 2.3 [1.6; 3.1] 30 0.0700 3.2 [2.2; 4.2]
Table 3 Overview of the data for four representative compounds
a HIV-1 IN–TRN-SR2 AlphaScreen  IC50 values and percentage inhibition (PIN) are presented. All compounds were tested at 50 µM
b EC50 and  CC50 values in MT4 cells are given as well as the percentage of protection against the cytopathic effect of HIV
c HeLaP4 cells were infected with a single-round virus expressing the firefly luciferase reporter gene (Fluc) in the presence of one of the compounds (100 µM) and the 
results are expressed as a percentage inhibition relative to the DMSO control
d For the PIC assay in HeLaP4 cells, p values (Mann–Whitney U test), compared to the DMSO control, are given
In vitro MT4 cells HeLaP4 cells
AlphaScreena MTTb Flucc PIC  assayd
IC50 (µM) PIN (%) EC50 (µM) CC50 (µM) % Protection PIN (%) p value
MVG010 54.6 37.1 > 100 100 6 34.2 0.1209
MVG030 33.6 71.6 > 97 97 25 23.3 0.0411
MVG036 37.6 105.6 > 55 65 46 – 0.0011
MVG044 17.1 75.9 > 250 > 250 22 16.3 0.00001
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rapid growth (and frequent cell divisions) of the cell cul-
ture-adapted MT-4 cells during the viral replication assay 
may relieve the bottleneck of nuclear import. Disassem-
bly and reassembly of the nuclear membrane during the 
frequent mitoses could give incoming viral PICs periodic 
access to the condensed, LEDGF/p75-decorated chroma-
tin, masking nuclear import defects. Second, while the 
single round antiviral activity assay gives a global view 
of viral replication after 72  h, the PIC assay is a kinetic 
assay, providing a snapshot of the population of cytoplas-
mic and nuclear PICs at 5  h after infection. As nuclear 
import is a bottleneck process [15], PICs accumulat-
ing at the nuclear periphery may remain there for some 
time before being bound and imported by TRN-SR2 (or 
being degraded). Depending on its affinity and kinetics, 
an inhibitor of the IN–TRN-SR2 interaction could delay 
the import process and shift PICs towards degradation in 
the cytoplasm. Our compounds may not induce sufficient 
delay in import and a few PICs may make it into the cell’s 
nucleus masking the inhibition.
One of the caveats of targeting pathogen-host protein–
protein interactions is the risk of inducing cellular toxic-
ity due to inhibition of the host protein function. Notably, 
none of the active classes exhibited prominent toxicity in 
the MTT/MT-4 assay.
Recently, De Houwer et al. [34] reported an IN mutant 
virus that is partially defective for interaction with TRN-
SR2 and nuclear import. Together with these findings, 
the identification of molecules inhibiting HIV-1 PIC 
nuclear import from a HTS campaign against the IN–
TRN-SR2 interaction underscores the importance of the 
interaction for HIV-1 nuclear import.
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